ArticleTranslational psychiatry2015
The positive effect on ketamine as a priming adjuvant in antidepressant treatment.
Article in Translational psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Sex Differences in Stress Response: Classical Mechanisms and Beyond.Current neuropharmacology · 2024Article
- The Duration of Stress Determines Sex Specificities in the Vulnerability to Depression and in the Morphologic Remodeling of Neurons and Microglia.Frontiers in behavioral neuroscience · 2022Article
- Strain-, Sex-, and Time-Dependent Antidepressant-like Effects of Cannabidiol.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Antidepressant activity of rose oxide essential oil: possible involvement of serotonergic transmission.Heliyon · 2021Article
- Advances in novel molecular targets for antidepressants.Progress in neuro-psychopharmacology & biological psychiatry · 2021Review
- Repeated Dosing of Ketamine in the Forced Swim Test: Are Multiple Shots Better Than One?Frontiers in psychiatry · 2021Review
- Behavioral and Neurochemical Effects of Extra Virgin Olive Oil Total Phenolic Content andMolecules (Basel, Switzerland) · 2020Article
- Psychoactive properties of BNN27, a novel neurosteroid derivate, in male and female rats.Psychopharmacology · 2020Article
- Chronic stress triggers divergent dendritic alterations in immature neurons of the adult hippocampus, depending on their ultimate terminal fields.Translational psychiatry · 2019Article
- The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder.Annual review of pharmacology and toxicology · 2019Review
- The neurobiology of depression, ketamine and rapid-acting antidepressants: Is it glutamate inhibition or activation?Pharmacology & therapeutics · 2018Review
- Current Status of Animal Models of Posttraumatic Stress Disorder: Behavioral and Biological Phenotypes, and Future Challenges in Improving Translation.Biological psychiatry · 2018Review
- The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Article
- Effect of Levodopa on Reward and Impulsivity in a Rat Model of Parkinson's Disease.Frontiers in behavioral neuroscience · 2017Article
- Exposure to Ketamine Anesthesia Affects Rat Impulsive Behavior.Frontiers in behavioral neuroscience · 2016Article
- Ketamine for depression: evidence, challenges and promise.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2015Article
- Sex-Dependent Ketamine Addiction-Like Behavior Profile Following Exposure to Chronic Mild Stress.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine observed in preclinical and clinical research makes it a promising therapeutic to improve current major depression (MD) treatment. Our work intended to evaluate whether the combined use of classic antidepressants (imipramine or fluoxetine) and ketamine would improve the antidepressant response. Using an animal model of depressive-like behavior, we show that the addition of ketamine to antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of antidepressants alone. In conclusion, our results suggest the need for a reappraisal of the current pharmacological treatment of MD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.